Pharma's Almanac TVPA TV
  • Follow the Completed Journey
  • Companies We've Met
  • AES Clean Technology
  • Altis Biosystems
  • Arranta Bio
  • Avara Pharmaceutical Services
  • Avid Bioservices
  • BioVectra
  • Centaur BPS
  • Dynamk Capital
  • ECRI
  • Evolve Biologics
  • Federal Equipment Company
  • Globyz
  • Inceptor Bio
  • IPS-Integrated Project Services
  • Olon
  • Pii
  • Polpharma Biologics
  • PPD
  • RoosterBio
  • SanaClis
  • Sanofi AIS
  • SGD Pharma
  • SPI Pharma
  • TriRx Pharmaceutical Services
  • Yourway
  • Follow the Completed Journey
  • Companies On The Road
  • Follow The Artist
  • ABS
  • aCGT Vector
  • Alconox Inc.
  • Andelyn Biosciences
  • Arranta Bio
  • Avid Bioservices
  • BDD
  • BIOVECTRA
  • DPS Group
  • Dynamk Capital
  • Environmental Systems Corporation
  • Federal Equipment Company
  • Genesis AEC
  • Globyz Biopharma Services
  • Grifols Partnership
  • IDT Biologika
  • Inceptor Bio
  • IPS-Integrated Project Services
  • Kineticos Life Sciences
  • MilliporeSigma
  • Montana BioScience Alliance
  • Olon
  • Rentschler Biopharma
  • SanaClis
  • Scorpion Biological Services
  • Secant Group
  • Tapemark
  • VITRONIC
Dashboard
Your Name
Your Email
  • Manage Account
  • Sign Out
Sign In
Register
    • Topics
        Products
        • ADC
        • API - Small Molecule
        • Biologics
        • Biopharmaceuticals
        • Biosimilars
        • Cell and Gene Therapy
        • DNA
        • Drug Product
        • Drug Substance
        • Equipment
        • Generics
        • Immunotherapy
        • Injectables
        • Monoclonal Antibody
        • Novel Therapeutics
        • Oral Solid Dosage
        • Orphan Drugs
        • Parenterals
        • Stem Cells
        • Vaccine
        Services
        • Big Data
        • Bioprocessing
        • Clinical Trials
        • Continuous Manufacturing
        • Diagnostics
        • Drug Delivery
        • Drug Development
        • Drug Discovery
        • Facility
        • Formulation
        • Innovation
        • Oncology
        • Patient Adherence
        • Patient Centric
        • Preclinical
        • Process Development
        • Quality
        • Regulatory
        • Research
        • Serialization
        Segment
        • Biomanufacturing
        • Biotechnology
        • CDMO
        • Consulting
        • CRO
        • Engineering
        • Equipment
        • Excipients
        • Healthcare
        • Intermediates
        • Logistics
        • Manufacturing
        • Packaging
        • Supply Chain
        Business
        • Agreement
        • Appointment
        • Business
        • Capacity Expansion
        • Collaboration
        • Growth
        • Investment
        • Licensing
        • M&A
        • Market Expansion
        • Market Intelligence
        • Market Prediction
        • New Facility
        • Strategic Partnership
    • Magazine
      • Archive
    • Reports
      • 2021 Cell & Gene Therapy Report
      • 2021 Monoclonal Antibody & Recombinant Protein Market Report
      • 2022 Sterile Drug Market Report
      • 2022 API Market Report
      • 2022 OSD Market Report
    • Community
    • Company A to Z
    • Follow the Journey
    • Companies On The Road
    • Follow The Artist
    • More+
      • Staffing
      • Media Kit

    Janssen Pharmaceuticals

    9 Articles Available

    Can't find what you're looking for? Try our advanced search.

    Digital Medicine

    PhysIQ Announces Strategic Collaboration to Scale Digital Medicine
    PR-M04-21-019

    Multiple Myeloma

    Janssen Reports Positive Results for DARZALEX® in Multiple Myeloma
    PAO-M12-19-NI-006

    FDA Approval

    Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
    PR-M10-19-NI-032

    Strategic Partnership

    nference Enters into an R&D Data Science Strategic Partnership with Janssen
    PR-M06-19-NI-013

    Drug Design

    Janssen, Iktos Collaborate on In Silico Drug Design
    PAO-M05-19-NI-022

    FDA

    Janssen Aims for Supplemental U.S. FDA Approval for INVOKANA®
    PAO-M04-19-NI-007

    New Drug Application

    Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
    PR-M04-19-NI-008

    HIV

    Long-Acting Injectable HIV Treatment Regimen of Rilpivirine and Cabotegravir Demonstrated Comparable Safety and Efficacy to Daily Oral HIV Therapy
    PR-M03-19-NI-033

    Approval

    Xarelto Gets Approval for Additional Indication
    PAO-M10-18-NI-019

    About Us
    That’s Nice Staffing
    More
    Media Kit Download Current Issue
    Your Account
    Manage Your Account Dashboard Sign Out
    Sign In Register
    Help
    Contact Us Support
    Nice Insight/That’s Nice

    89 Fifth Avenue
    Fifth Floor
    New York
    NY 10003-3020

    New York – San Diego – Chicago
    London – Frankfurt – Shanghai

    Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.

    © PHARMA’S ALMANAC 2022 Terms and Conditions